Pharmacogenetics in breast cancer: focus on hormone therapy, taxanes, trastuzumab and bevacizumab
- 7 April 2010
- journal article
- review article
- Published by Informa Healthcare in Expert Opinion on Investigational Drugs
- Vol. 19 (sup1), S41-S50
- https://doi.org/10.1517/13543781003732701
Abstract
Breast cancer is the most common female cancer, with more than one million new patients diagnosed annually worldwide. The great heterogeneity, in terms of prognosis and outcome, within patients with the same clinical and pathological characteristics may limit the potential for personalized therapy. Most of the cytotoxic agents and new targeted agents have a narrow therapeutic index and the administration of an equal dose may result in a wide range of toxicities as well as to different antitumor efficacy. Inter-subject variability in drug toxicity and response is common during treatment, so that individualization of treatments is an important issue. Pharmacogenetics is the study of how inter-individual variations in the DNA sequence of specific genes may affect drug response and toxicity. This article highlights the clinical use of determination of polymorphisms of important human drug-metabolizing cytochrome P450s, ABCB1, IgG fragment C receptors and vascular endothelial growth factor, which are responsible of the large inter-individual variability in drug metabolism and clearance of the agents commonly used in breast cancer treatment, such as tamoxifen, aromatase inhibitors, taxanes, trastuzumab and bevacizumab.Keywords
This publication has 70 references indexed in Scilit:
- The HER-2 Receptor and Breast Cancer: Ten Years of Targeted Anti–HER-2 Therapy and Personalized MedicineThe Oncologist, 2009
- Gene Expression Signatures, Clinicopathological Features, and Individualized Therapy in Breast CancerJAMA, 2008
- The Prognostic Role of a Gene Signature from Tumorigenic Breast-Cancer CellsNew England Journal of Medicine, 2007
- Sorting Out Breast-Cancer Gene SignaturesNew England Journal of Medicine, 2007
- Endoxifen, a Secondary Metabolite of Tamoxifen, and 4-OH-Tamoxifen Induce Similar Changes in Global Gene Expression Patterns in MCF-7 Breast Cancer CellsJournal of Pharmacology and Experimental Therapeutics, 2006
- Active Tamoxifen Metabolite Plasma Concentrations After Coadministration of Tamoxifen and the Selective Serotonin Reuptake Inhibitor ParoxetineJNCI Journal of the National Cancer Institute, 2003
- Impact of Body-Size Measures on Irinotecan Clearance: Alternative Dosing RecommendationsJournal of Clinical Oncology, 2002
- Initial sequencing and analysis of the human genomeNature, 2001
- Pharmacogenetics and adverse drug reactionsThe Lancet, 2000
- Inherited variations in drug-metabolizing enzymes: Significance in clinical oncologyMolecular Diagnosis, 1999